finance

Barclays downgrades Reata Pharma to 'equalweight' with a price target of $172.00




Barclays downgrades Reata Pharma to 'equalweight' with a price target of $172.00



READ SOURCE

Readers Also Like:  Inflation is affecting travel, but that doesn't mean it's slowing down

This website uses cookies. By continuing to use this site, you accept our use of cookies.